

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Sep 2026

Comparing the effect of Cranberry and Nitrofurantoin on recurrent urinary tract infection in children

Protocol summary

Study aim

Survey of cranberry capsule on prevention of recurrent urinary tract infection in children and its replacement with routine antibiotics

Design

A randomized clinical trial with control group, parallel group design and without blinding, with a sample size of 50 patients

Settings and conduct

The study place will be the Nephrology clinic of Sabzevar Heshmatie Hospital.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Children with recurrent urinary tract infection; Written consent from parents. Non-inclusion criteria: Children less than one month; Patients who are unable to use the medication in question due to the patient's departure from the usual route to complication or deterioration of the patient's general condition.

Intervention groups

Intervention group: Children with recurrent urinary tract infection will be treated using 300 mg cranberry capsule daily for one month. Control group: Children with recurrent urinary tract infection will receive 10 mg /kg Nitrofurantoin (an antibiotic) daily for 1 month.

Main outcome variables

Urinary tract infection

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191207045640N1**

Registration date: **2020-02-11, 1398/11/22**

Registration timing: **retrospective**

Last update: **2020-02-11, 1398/11/22**

Update count: **0**

Registration date

2020-02-11, 1398/11/22

Registrant information

Name

Zahra Boluki

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 51 4262 7414

Email address

zahra.boluki@yahoo.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-01-05, 1398/10/15

Expected recruitment end date

2020-01-20, 1398/10/30

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Comparing the effect of Cranberry and Nitrofurantoin on recurrent urinary tract infection in children

Public title

Surveying cranberry effect on urinary tract infection in children

Purpose

Prevention

Inclusion/Exclusion criteria

Inclusion criteria:

All children with recurrent urinary tract infection
Written parental consent

Exclusion criteria:

Children under the age of one month Parental dissatisfaction Patients who are unable to use the medication in question due to the patient's departure from the usual route to complication or deterioration

Age

From **1 month** old to **16 years** old

Gender

Both

Phase

2

Groups that have been masked

No information

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

In order to do simple random allocation, the numbered cards with odds and even numbers are placed in a bag and an individual unaware of the numbers on the cards will give the cards to the parent. Therefore the patients will be randomly assigned to the intervention and control groups.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Sabzevar University of Medical Sciences

Street address

Heshmati Hospital, Assad Abadi street, Sabzavar

City

Sabzevar

Province

Razavi Khorasan

Postal code

9319719746

Approval date

2019-12-08, 1398/09/17

Ethics committee reference number

IR.MEDSAB.REC.1398.073

Health conditions studied**1****Description of health condition studied**

Recurrent urinary tract infection

ICD-10 code

N39.0

ICD-10 code description

Urinary tract infection, site not specified

Primary outcomes**1****Description**

Urinary tract infection

Timepoint

One week after treatment, then every one month up to three months and then every two months up to 6 months

Method of measurement

Urine analysis and urine culture

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: Blueberry capsule 300 mg once daily for three months after treatment for UTI and for children who cannot use the capsule, the mother is asked to dissolve and use the contents of the capsule in water.

Category

Treatment - Drugs

2**Description**

Control group: Nitrofurantoin antibiotic with prophylactic dose (one third of therapeutic dose) 1 mg / kg daily (maximum daily dose 100 mg) in the form of 50 mg tablets Mehr Daro Company based on baby weight for three months They will receive urinary tract infection after treatment.

Category

Treatment - Drugs

Recruitment centers**1****Recruitment center****Name of recruitment center**

Heshmati Specialty Hospital

Full name of responsible person

Zahra Boluki

Street address

Assad Abadi street

City

Sabzevar

Province
Razavi Khorasan
Postal code
9319719746
Phone
+98 51 4261 4974
Email
zahra.boluki@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Sabzevar University of Medical Sciences
Full name of responsible person
Hosen Shariatmadari
Street address
Sabzevar University of Medical Sciences
Headquarters, Assad Abadi street
City
Sabzevar
Province
Razavi Khorasan
Postal code
9613873119
Phone
+98 51 4401 1096
Email
vc.dmr@medsab.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Sabzevar University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Sabzevar University of Medical Sciences
Full name of responsible person
Zahra Boluki
Position
Intern
Latest degree
A Level or less
Other areas of specialty/work

Medical Intern
Street address
Puyesh 1, Puyesh alley, Adab street, Basij Town
City
Neyshaboor
Province
Razavi Khorasan
Postal code
9319719746
Phone
+98 51 4261 4974
Email
zahra.boluki@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Sabzevar University of Medical Sciences
Full name of responsible person
Zahra Boluki
Position
intern
Latest degree
A Level or less
Other areas of specialty/work
Medical Education
Street address
Puyesh 1, Puyesh alley, Adab street, Basij Town
City
Neyshaboor
Province
Razavi Khorasan
Postal code
9319719746
Phone
+98 51 4261 4974
Email
zahra.boluki@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Sabzevar University of Medical Sciences
Full name of responsible person
Zahra Boluki
Position
intern
Latest degree
A Level or less
Other areas of specialty/work
Medical Education
Street address
Puyesh 1, Puyesh alley, Adab street, Basij Town
City
Neyshaboor
Province
Razavi Khorasan
Postal code
9319719746

Phone

+98 51 4261 4974

Email

zahra.boluki@yahoo.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

I haven't decided yet - its release schedule is still unclear

When the data will become available and for how**long**

I haven't decided yet - its release schedule is still unclear

To whom data/document is available

I haven't decided yet - its release schedule is still unclear

Under which criteria data/document could be used

I haven't decided yet - its release schedule is still unclear

From where data/document is obtainable

I haven't decided yet - its release schedule is still unclear

What processes are involved for a request to access data/document

I haven't decided yet - its release schedule is still unclear

Comments